Live Stock Coverage: Natus Medical Inc Can’t Be More Safe. Trades Significantly Higher

Live Stock Coverage: Natus Medical Inc Can't Be More Safe. Trades Significantly Higher

The stock of Natus Medical Inc (NASDAQ:BABY) is a huge mover today! About 347,971 shares traded hands. Natus Medical Inc (NASDAQ:BABY) has risen 6.46% since March 16, 2016 and is uptrending. It has outperformed by 0.92% the S&P500.
The move comes after 5 months positive chart setup for the $1.38 billion company. It was reported on Oct, 19 by Barchart.com. We have $50.88 PT which if reached, will make NASDAQ:BABY worth $276.00 million more.

Natus Medical Inc (NASDAQ:BABY) Ratings Coverage

Out of 4 analysts covering Natus Medical (NASDAQ:BABY), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Natus Medical has been the topic of 6 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Thursday, October 22 by TH Capital. The firm has “Outperform” rating given on Tuesday, September 13 by Raymond James. Benchmark initiated Natus Medical Inc (NASDAQ:BABY) rating on Tuesday, October 4. Benchmark has “Buy” rating and $55 price target. The stock has “Buy” rating given by TH Capital on Tuesday, January 12. On Tuesday, April 5 the stock rating was maintained by Roth Capital with “Buy”. As per Thursday, July 23, the company rating was maintained by TH Capital.

According to Zacks Investment Research, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories.”

Insitutional Activity: The institutional sentiment increased to 1.07 in Q2 2016. Its up 0.13, from 0.94 in 2016Q1. The ratio improved, as 34 funds sold all Natus Medical Inc shares owned while 51 reduced positions. 23 funds bought stakes while 68 increased positions. They now own 28.47 million shares or 0.50% less from 28.61 million shares in 2016Q1.
Northern Trust Corporation has 475,872 shares for 0.01% of their US portfolio. Moreover, Lazard Asset Management Ltd Liability Co has 0% invested in Natus Medical Inc (NASDAQ:BABY) for 27,250 shares. Alphaone Investment Svcs Lc reported 100,465 shares or 1.4% of all its holdings. Aperio Ltd Liability Co holds 0% of its portfolio in Natus Medical Inc (NASDAQ:BABY) for 5,698 shares. Comerica Bank & Trust has invested 0.01% of its portfolio in Natus Medical Inc (NASDAQ:BABY). Deutsche State Bank Ag last reported 0% of its portfolio in the stock. Louisiana State Employees Retirement accumulated 14,700 shares or 0.03% of the stock. Pax Mngmt Ltd Liability Company has 0.94% invested in the company for 430,000 shares. Trexquant L P last reported 0.04% of its portfolio in the stock. Mckinley Mngmt Limited Liability Company Delaware has 100 shares for 0% of their US portfolio. Moreover, X Ltd has 0% invested in Natus Medical Inc (NASDAQ:BABY) for 146 shares. Mirador Capital Partners L P holds 7,045 shares or 0.27% of its portfolio. Blackrock Grp Inc Limited has 0% invested in the company for 40,645 shares. Geode Capital Mngmt Ltd Liability Corporation holds 292,027 shares or 0.01% of its portfolio. Jpmorgan Chase And Com holds 0% of its portfolio in Natus Medical Inc (NASDAQ:BABY) for 97,565 shares.

Insider Transactions: Since April 22, 2016, the stock had 1 insider buy, and 1 sale for $211,790 net activity. 10,000 shares were bought by HAWKINS JAMES B, worth $384,840 on Wednesday, September 28. $250,324 worth of Natus Medical Inc (NASDAQ:BABY) shares were sold by TRAVERSO KENNETH M. 5,000 shares with value of $173,050 were sold by GUNST ROBERT A on Tuesday, April 26. Engibous Doris also sold $163,400 worth of Natus Medical Inc (NASDAQ:BABY) shares.

More notable recent Natus Medical Inc (NASDAQ:BABY) news were published by: Fool.com which released: “Why Natus Medical Inc Slipped Today” on September 26, 2016, also Fool.com with their article: “3 Things to Watch As Natus Medical Inc Reports Earnings” published on July 18, 2016, Fool.com published: “Why Natus Medical Inc. Reported Lower Today” on April 04, 2016. More interesting news about Natus Medical Inc (NASDAQ:BABY) were released by: Fool.com and their article: “How Natus Medical Inc. Got Back on Track” published on July 20, 2016 as well as Fool.com‘s news article titled: “Natus Medical Inc Says Adios to Venezuela Guidance” with publication date: April 20, 2016.

BABY Company Profile

Natus Medical Incorporated, incorporated on July 20, 2000, is a well-known provider of newborn care and neurology healthcare services and products used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company’s segment is neurology and newborn care product families. The Company’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. The Firm is organized into two strategic business units: Neurology and Newborn Care.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment